MRNA Stock Recent News
MRNA LATEST HEADLINES
The FDA said Tuesday it will limit future Covid vaccines to older and at-risk Americans. The move buoyed Moderna, BioNTech and Novavax.
U.S. equities were lower at midday, dragged by tech and travel stocks. The Dow Jones Industrial Average, S&P 500, and Nasdaq were all lower.
Moderna's share price has collapsed from $500 to $25, but I believe the selloff is overdone, and the stock is deeply oversold. Short squeeze potential, a robust pipeline, and long-term mRNA/AI opportunities could drive a significant rebound, despite near-term losses and vaccine skepticism. Moderna's strong balance sheet, insider buying, and promising oncology candidates add to my conviction for a small, speculative position.
S&P 500 and Nasdaq edge higher mid-session as weak sentiment data tempers gains. Traders assess inflation risks and tariff uncertainty.
Equity markets are full of bargains -- stocks that have performed terribly in recent months, whether due to trade-related marketwide issues or company-specific troubles, but could bounce back once things improve. There are also companies that are not performing well and are unlikely to rebound anytime soon; that's the kind investors should stay away from.
Subscribers to Chart of the Week received this commentary on Sunday, May 11.
The vaccine maker, which has partnered with OpenAI since 2023, is rethinking how it does workforce planning thanks to the growing capabilities of AI and other tech.
CAMBRIDGE, MA / ACCESS Newswire / May 8, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Bernstein's 41st Annual Strategic Decisions Conference (SDC), on Thursday, May 29th at 10:00am ET A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website. investors.modernatx.com.
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.
Moderna plans to launch 10 new marketed products over the next three years, aiming to diversify a revenue base, which is still heavily reliant on COVID-19 vaccine sales.